23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
23:03 , Jan 25, 2018 |  BC Extra  |  Financial News

Follow-on roundup: Audentes, Iovance

At least six companies have priced follow-ons since Wednesday’s market close, raising more than $600 million. Gene therapy company Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $201.3 million after hours on Wednesday through the sale of 5.8...
19:36 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Albireo gets $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat to treat chronic constipation. The approval triggered about $55 million in payments to the...
16:26 , Jan 19, 2018 |  BC Extra  |  Company News

Albireo receives $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat on Friday to treat chronic constipation. The approval triggered about $55 million in payments...
18:24 , Jan 12, 2018 |  BC Week In Review  |  Company News

Albireo in elobixibat royalty deal with HealthCare Royalty

HealthCare Royalty Partners (Stamford, Conn.) entered into a deal with the Elobix AB subsidiary of Albireo Pharma Inc. (NASDAQ:ALBO). In exchange for royalties and milestones related to elobixibat and payable by the EA Pharma Co....
22:46 , Jan 8, 2018 |  BC Extra  |  Company News

HealthCare Royalty in deals with Agenus, Albireo

Agenus Inc. (NASDAQ:AGEN) said it will sell to HealthCare Royalty Partners (Stamford, Conn.) royalty rights on sales of vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) containing Agenus' QS-21 Stimulon adjuvant. The biotech will receive $190 million...
22:46 , Feb 8, 2017 |  BC Week In Review  |  Clinical News

Elobixibat regulatory update

Eisai’s EA Pharma Co. Ltd. subsidiary submitted an NDA in Japan for elobixibat to treat chronic constipation. EA has exclusive rights to elobixibat for gastrointestinal disorders in Japan and other Asian countries from Albireo. EA...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Elobixibat: Phase III data

Top-line data from a double-blind, Japanese Phase III trial in patients with chronic constipation showed that elobixibat for 14 days met the primary endpoint of improving the number of weekly SBMs from baseline to week...
07:00 , Oct 3, 2016 |  BC Extra  |  Clinical News

Albireo's elobixibat meets in Japanese Phase III study

Albireo AB (Gothenburg, Sweden) said elobixibat (AJG533/ A3309 ) met the primary endpoint in a Japanese Phase III study to treat chronic constipation. Compared with placebo, elobixibat significantly improved the number of weekly spontaneous bowel...